Dynavax Technologies (LTS:0IDA) Total Liabilities : $368.1 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dynavax Technologies Total Liabilities?

Dynavax Technologies's Total Liabilities for the quarter that ended in Mar. 2024 was $368.1 Mil.

Dynavax Technologies's quarterly Total Liabilities increased from Sep. 2023 ($368.02 Mil) to Dec. 2023 ($375.02 Mil) but then declined from Dec. 2023 ($375.02 Mil) to Mar. 2024 ($368.09 Mil).

Dynavax Technologies's annual Total Liabilities declined from Dec. 2021 ($816.87 Mil) to Dec. 2022 ($404.84 Mil) and declined from Dec. 2022 ($404.84 Mil) to Dec. 2023 ($375.02 Mil).

Dynavax Technologies Total Liabilities Historical Data

The historical data trend for Dynavax Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Total Liabilities Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

270.78

294.58

816.87

404.84

375.02

Dynavax Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															406.19	359.23	368.02	375.02	368.09

Dynavax Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Dynavax Technologies's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	62.195	+	(252.418	+	60.411
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	375.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	997.096	-	622.072
	=	375.0

Dynavax Technologies's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	56.002	+	(251.543	+	60.54
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	368.1

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	986.565	-	618.48
	=	368.1

Dynavax Technologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (LTS:0IDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (LTS:0IDA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DVAX:USA DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (LTS:0IDA) Headlines

No Headlines